Enlivex Therapeutics
ENLV
ENLV
17 hedge funds and large institutions have $2.96M invested in Enlivex Therapeutics in 2024 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 4 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
8.23% more ownership
Funds ownership: 1.75% → 9.99% (+8.2%)
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
Holders
17
Holding in Top 10
–
Calls
$54K
Puts
$22K
Top Buyers
| 1 | +$2.41M | |
| 2 | +$245K | |
| 3 | +$35.2K | |
| 4 |
Goldman Sachs
New York
|
+$16.2K |
| 5 |
Renaissance Technologies
New York
|
+$2.56K |
Top Sellers
| 1 | -$258K | |
| 2 | -$210K | |
| 3 | -$69K | |
| 4 |
JPMorgan Chase & Co
New York
|
-$9.83K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$4.39K |